Immuneering Co. (NASDAQ:IMRX – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 1,520,000 shares, a drop of 6.7% from the September 30th total of 1,630,000 shares. Based on an average daily trading volume, of 6,690,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 7.2% of the company’s shares are sold short.
Immuneering Stock Up 0.5 %
NASDAQ IMRX opened at $1.87 on Friday. The firm has a market cap of $55.45 million, a price-to-earnings ratio of -0.98 and a beta of -0.45. The business has a 50-day moving average price of $2.02 and a 200-day moving average price of $1.59. Immuneering has a twelve month low of $1.00 and a twelve month high of $8.89.
Immuneering (NASDAQ:IMRX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Research analysts expect that Immuneering will post -1.89 EPS for the current fiscal year.
Institutional Trading of Immuneering
Analyst Ratings Changes
A number of research analysts have issued reports on IMRX shares. Chardan Capital lowered their price objective on Immuneering from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Immuneering in a research note on Friday, September 13th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.60.
Check Out Our Latest Stock Analysis on IMRX
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
- Five stocks we like better than Immuneering
- Why Invest in High-Yield Dividend Stocks?
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- How Technical Indicators Can Help You Find Oversold Stocks
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- There Are Different Types of Stock To Invest In
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.